The estimated Net Worth of Ken Haas is at least $530 millier dollars as of 29 November 2010. Ken Haas owns over 500,000 units of Zogenix Inc stock worth over $529,571 and over the last 14 years Ken sold ZGNX stock worth over $0.
Ken has made over 1 trades of the Zogenix Inc stock since 2010, according to the Form 4 filled with the SEC. Most recently Ken bought 500,000 units of ZGNX stock worth $2,000,000 on 29 November 2010.
The largest trade Ken's ever made was buying 500,000 units of Zogenix Inc stock on 29 November 2010 worth over $2,000,000. On average, Ken trades about 500,000 units every 0 days since 2010. As of 29 November 2010 Ken still owns at least 19,849 units of Zogenix Inc stock.
You can see the complete history of Ken Haas stock trades at the bottom of the page.
Ken's mailing address filed with the SEC is C/O ABINGWORTH BIOVENTURES, 3000 SAND HILL RD., B4-135, MENLO PARK, CA, 94025.
Over the last 14 years, insiders at Zogenix Inc have traded over $5,100,850 worth of Zogenix Inc stock and bought 57,764,538 units worth $193,451,745 . The most active insiders traders include Advisors Llcperceptive Life..., Nicole Vitullo et Jesse I Treu. On average, Zogenix Inc executives and independent directors trade stock every 34 days with the average trade being worth of $13,059,406. The most recent stock trade was executed by Erle T Mast on 1 February 2022, trading 1,250 units of ZGNX stock currently worth $15,000.
Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company's first rare disease therapy, FINTEPLA® (fenfluramine) oral solution has been approved by the U.S. FDA and the European Medicines Agency and is in development in Japan for the treatment of seizures associated with Dravet syndrome, a rare, severe lifelong epilepsy. The company has two additional late-stage development programs underway: one for FINTEPLA for the treatment of seizures associated with Lennox-Gastaut syndrome, another rare epilepsy, and one for MT1621, an investigational therapy for the treatment of a rare genetic disorder called TK2 deficiency. Zogenix is also collaborating with Tevard Biosciences to identify and develop potential next-generation gene therapies for Dravet syndrome and other genetic epilepsies.
Zogenix Inc executives and other stock owners filed with the SEC include: